ACADIA Pharmaceuticals (NASDAQ:ACAD) PT Set at $39.00 by Stifel Nicolaus
ACADIA Pharmaceuticals (NASDAQ:ACAD) has been assigned a $39.00 price target by equities research analysts at Stifel Nicolaus in a research note issued to investors on Monday, TipRanks reports. The brokerage presently has a “hold” rating on the biopharmaceutical company’s stock. Stifel Nicolaus’ price target indicates a potential downside of 5.77% from the stock’s current price.
ACAD has been the topic of several other reports. Bank of America set a $31.00 target price on shares of ACADIA Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, July 31st. Raymond James increased their target price on ACADIA Pharmaceuticals from $40.00 to $43.00 and gave the company a “strong-buy” rating in a report on Friday, May 31st. Canaccord Genuity raised ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating and raised their target price for the stock from $29.00 to $50.00 in a research report on Tuesday. Zacks Investment Research downgraded ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday. Finally, HC Wainwright set a $60.00 price target on ACADIA Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday. Five investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. ACADIA Pharmaceuticals has an average rating of “Buy” and an average target price of $43.31.
Shares of ACADIA Pharmaceuticals stock traded up $0.17 during trading on Monday, hitting $41.39. The stock had a trading volume of 3,218,571 shares, compared to its average volume of 1,502,557. The stock has a 50 day simple moving average of $28.11 and a 200 day simple moving average of $26.40. The company has a market capitalization of $5.61 billion, a PE ratio of -21.34 and a beta of 2.75. The company has a quick ratio of 6.79, a current ratio of 6.85 and a debt-to-equity ratio of 0.02. ACADIA Pharmaceuticals has a 1 year low of $13.19 and a 1 year high of $43.98.
In other news, Director James M. Daly sold 30,000 shares of the company’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $37.80, for a total value of $1,134,000.00. Following the transaction, the director now directly owns 30,000 shares of the company’s stock, valued at $1,134,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Eric Alejandro Miller sold 28,467 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $39.49, for a total value of $1,124,161.83. The disclosure for this sale can be found here. Insiders have sold a total of 63,112 shares of company stock valued at $2,449,443 in the last three months. Company insiders own 29.40% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in ACAD. Clearbridge Investments LLC acquired a new position in ACADIA Pharmaceuticals in the 1st quarter worth about $27,000. Twin Tree Management LP purchased a new stake in shares of ACADIA Pharmaceuticals during the 1st quarter worth about $29,000. Steward Partners Investment Advisory LLC purchased a new stake in shares of ACADIA Pharmaceuticals during the 2nd quarter worth about $42,000. Quantamental Technologies LLC acquired a new stake in shares of ACADIA Pharmaceuticals during the 2nd quarter valued at about $57,000. Finally, NumerixS Investment Technologies Inc acquired a new stake in shares of ACADIA Pharmaceuticals during the 2nd quarter valued at about $107,000. 97.38% of the stock is owned by hedge funds and other institutional investors.
About ACADIA Pharmaceuticals
ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
Featured Article: Diversification in Your Portfolio
Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.